Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genmab has reported that Roche has filed an investigational new drug application with the FDA for an antibody developed under their collaboration.
Subscribe to our email newsletter
Genentech and Roche are collaborating on development of the antibody which selectively blocks the interaction of the OX40 ligand and its receptor. The companies are evaluating the antibody for the treatment of asthma. Genmab will receive a milestone payment from Roche which does not influence Genmab’s financial guidance for 2007.
Under the agreement with Roche, Genmab utilizes its broad antibody expertise and development capabilities to create human antibodies to a broad range of disease targets identified by Roche. Genmab receives milestone and royalty payments based on successful products. In certain circumstances, Genmab may obtain rights to develop products based on disease targets identified by Roche.
Lisa Drakeman, CEO of Genmab, said: “Four of the antibodies developed by Genmab under our collaboration with Roche have now entered the clinic.”